Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jjco/hyu204PMID 25489004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

  2014cited by this paper
• Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

  2014cited by this paper
• Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

  2014cited by this paper
• Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

  2013cited by this paper
• Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

  2013cited by this paper
• International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers

  2013cited by this paper
• Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

  2012influential reference
• Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

  2012influential reference
• Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

  2012cited by this paper
• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

  2012influential reference
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012cited by this paper
• Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

  2012influential reference
• A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

  2012cited by this paper
• Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients

  2011cited by this paper
• ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

  2011cited by this paper
• Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses

  2011cited by this paper
• Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

  2011cited by this paper
• A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

  2010cited by this paper
• Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

  2010influential reference
• Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

  2010cited by this paper
• Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma

  2010cited by this paper
• Report on the First International Workshop on interim-PET scan in lymphoma

  2009cited by this paper
• Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

  2009cited by this paper
• ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

  2009cited by this paper
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

  2009cited by this paper
• Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

  2008cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007influential reference
• The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

  2006cited by this paper
• The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

  2006cited by this paper
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

  2006cited by this paper
• Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

  2006cited by this paper
• Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

  2006cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

  2005cited by this paper
• Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab

  2005cited by this paper
• Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

  2005cited by this paper
• Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

  2005cited by this paper
• ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

  2005cited by this paper
• ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.

  2004influential reference
• Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

  2003cited by this paper
• Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  2003cited by this paper
• Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

  2003cited by this paper
• Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

  2003cited by this paper
• Treatment of relapsed CD 20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

  2002cited by this paper
• A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE

  2000cited by this paper
• A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

  1998cited by this paper
• Gonadal function following ABVD therapy for Hodgkin's disease.

  1997cited by this paper
• Incidence of second cancers in patients treated for Hodgkin's disease.

  1995cited by this paper
• Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

  1992cited by this paper
• Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

  1989cited by this paper
• Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.

  1985cited by this paper
• Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

  1980cited by this paper

• Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.

  2021cites this paper
• Hodgkin Lymphomas

  2020cites this paper
• Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

  2020cites this paper
• Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

  2017cites this paper
• Effective chemomobilization with etoposide and cytarabine (EC regimen) in lymphoma patients: a single-center, retrospective, observational study

  2017cites this paper
• Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients

  2017cites this paper
• Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

  2015cites this paper
• Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

  2015cites this paper
• Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

  2015cites this paper